Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors
The Journal of Clinical Pharmacology · 2025-09 · 65 (9) · 1096-1105
DOI: 10.1002/jcph.70024 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 08.04.2025. Verfasst von Mary P Choules und 4 weiteren Autor:innen. Beteiligte Einrichtung: Astellas Pharma, Inc., Northbrook, IL, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP1A2 Inhibitors, Models, Biological. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Astellas Pharma, Inc, Astellas Pharma Global Development.
Abstract (Originalsprache)
Fezolinetant is a non‐hormonal, selective neurokinin 3 receptor antagonist approved in multiple countries including the United States, in Europe, and in Asia for the treatment of moderate to severe vasomotor symptoms in menopausal women. Fezolinetant is primarily metabolized by CYP1A2 and was found to be a sensitive substrate for CYP1A2 metabolism based on a clinical DDI study with strong CYP1A2 inhibitor, fluvoxamine. Therefore, coadministration with CYP1A2 inhibitors or inducers (such as smoking) could lead to changes in fezolinetant exposure. A physiological‐based pharmacokinetic (PBPK) model was built for fezolinetant using the Simcyp simulator software with in vitro and in vivo data. The final verified model was used to predict fezolinetant exposure following coadministration with mexiletine (moderate CYP1A2 inhibitor), ciprofloxacin (moderate CYP1A2 inhibitor), and cimetidine (weak CYP1A2 inhibitor). Depending on the dosing regimen of the inhibitor and the meal status, coadministration with a weak CYP1A2 inhibitor, such as cimetidine, was predicted to increase fezolinetant C max by 1.30 to 1.36 and AUC inf by 1.61 to 2.01 fold. A moderate CYP1A2 inhibitor, such as mexiletine, was predicted to increase fezolinetant C max by 1.36 to 1.59 fold and AUC inf by 3.38 to 4.61 fold. Another moderate CYP1A2 inhibitor, ciprofloxacin, was predicted to increase fezolinetant C max by 1.39 to 1.49 fold and AUC inf by and 1.99 to 2.33 fold. The results of the PBPK analysis supported global labeling language statements for fezolinetant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Astellas Pharma, Inc., Northbrook, IL, USA.
- Astellas Pharma, Inc., Tokyo, Japan.
ORCID-Profile: Mary P Choules, Jace C Nielsen
Förderung
- Astellas Pharma, Inc
- Astellas Pharma Global Development
Zitieren
APA
Choules, M. P., Otsuka, Y., Nielsen, J. C., Iwai, M., & Bonate, P. L. (2025). Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors. The Journal of Clinical Pharmacology, 65(9), 1096-1105. https://doi.org/10.1002/jcph.70024
Vancouver
Choules MP, Otsuka Y, Nielsen JC, Iwai M, Bonate PL. Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors. The Journal of Clinical Pharmacology. 2025;65(9):1096-1105. doi:10.1002/jcph.70024
BibTeX
@article{Choules2025,
author = {Choules, Mary P and Otsuka, Yukio and Nielsen, Jace C and Iwai, Megumi and Bonate, Peter L},
title = {Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
volume = {65},
number = {9},
pages = {1096--1105},
doi = {10.1002/jcph.70024}
}
EUVIMED